Get all your news in one place.

100's of premium titles.
One app.

Start reading

Get all your news in one place.

100's of premium titles. One news app.

Start reading

UNCOVERED: Lyra org - The Untold Story

Fizik’s new Lyra shoe is designed for 'modern riding positions', but what does that mean and is it even needed?

New shoes bring aesthetics and tech from Fizik’s top spec shoes to a lower price, with a wider toe box and lower drop

Cycling News

New Fizik Lyra shoe brings pro-level features to a more palatable price point

Double Li2 dials, a breathable upper, and a wider toebox make for an attractive upgrade this summer

Cycling Weekly

Hollyland launches its first webcam, and it looks incredible!

This 4K webcam uses a sensor that is bigger than most and can be paired with a wireless mic

Digital Camera World

From analysis to the latest developments in health,
read the most diverse news in one place.

Young Edinburgh stage stars take to the road for first tour

A GROUP of teenage performers based in one of Edinburgh’s most disadvantaged areas is to embark on their first tour...

The National (Scotland)

Your ultimate summer 2024 dress guide for work and weekend — from bold florals and denim to the new boho

Win at style this summer season with Victoria Moss’s ultimate guide to the best dresses out there

Evening Standard

Govee takes on Philips Hue with two new smart floor lamps

Introducing the Floor Lamp 2 and Floor Lamp Pro

Important Biotech Catalysts For September 13, 2022 - End Of The Day Summary

Akero Therapeutics (NASDAQ:AKRO) revealed topline data from HARMONY, a 24-week Phase 2b study evaluating the efficacy and safety of its lead product candidate efruxifermin (EFX) in patients with pre-cirrhotic nonalcoholic steatohepatitis (NASH), the study met its primary endpoint for both the 50mg and 28mg EFX dose groups. Akero Therapeutics shares…

Benzinga

Read news from The Economist, FT, and more,
with one subscription

Lyra Therapeutics's Return On Capital Employed Insights

According to data from Benzinga Pro, during Q1, Lyra Therapeutics's (NASDAQ:LYRA) reported sales totaled $5.37 million. Despite a 48.51% increase in earnings, the company posted a loss of $7.01 million.

Benzinga

25 huge gigs happening in Ireland this summer including Red Hot Chili Peppers, Elton John and more

It was hard to narrow it down to just 25, but here are some of the biggest concerts to catch over the next few months.

Irish Mirror

Peak Sales Potential For This ENT-Focused Stock Is Under-Appreciated, Says Cantor

Cantor initiated coverage on Lyra Therapeutics Inc (NASDAQ:LYRA) with an Overweight rating and a price target of $15 (166% upside). According to the analyst, Lyra product pipeline's peak sales potential is under-appreciated, and it expects upward earnings estimate revisions to potentially move LYRA's stock higher. LYRA is well-positioned with a portfolio of products to…

Benzinga

Recap: Lyra Therapeutics Q1 Earnings

Lyra Therapeutics (NASDAQ:LYRA) reported its Q1 earnings results on Tuesday, May 10, 2022 at 07:00 AM. Here's what investors need to know about the announcement.

Benzinga

28 Stocks Moving In Friday's Mid-Day Session

Gainers Lyra Therapeutics, Inc. (NASDAQ: LYRA) shares climbed 33.3% to $5.78 as the company reported a private placement for gross proceeds of $110.5 million.

Benzinga

Lyra Therapeutics Stock Surges On Equity Raise Of $100M

Lyra Therapeutics Inc (NASDAQ:LYRA) has announced a private placement of approximately $100.5 million. The Company has offered 18.8 million common shares at $4.22 per share and pre-funded warrants to purchase an aggregate of 5 million shares with an exercise price of $0.001 per share, at $4.219 per share. Each pre-funded warrant will…

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Red Hot Chili Peppers

US Food and Drug Administration

62 stories

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.